41st week of 2020 patent applcation highlights part 12 |
Patent application number | Title | Published |
20200316188 | BROAD AND LONG-LASTING INFLUENZA VACCINE - Provided herein are monovalent pharmaceutical compositions (vaccine compositions) and methods for inducing a multi-arm (mucosal, humoral and cell-mediated) immune response and extended seroprotection of at least 12 months post vaccination against influenza virus. | 2020-10-08 |
20200316189 | VACCINATION IN NEWBORNS AND INFANTS - The present invention relates to vaccines comprising at least one mRNA encoding at least one antigen for use in the treatment of a disease in newborns and/or infants, preferably exhibiting an age of not more than 2 years, preferably of not more than 1 year, more preferably of not more than 9 months or even 6 months, wherein the treatment comprises vaccination of the newborn or infant and eliciting an immune response in said newborn or infant. The present invention is furthermore directed to kits and kits of parts comprising such a vaccine and/or its components and to methods applying such a vaccine or kit. | 2020-10-08 |
20200316190 | PSGL-1 (P-SELECTIN GLYCOPROTEIN LIGAND-1) TO INACTIVATE ALL ENVELOPED VIRUSES FOR PRODUCING LIVE-ATTENUATED VACCINES - Embodiments relate to a method comprising (a) expressing a vector comprising a PSGL-1 (P-selectin glycoprotein ligand-1) or a mutant thereof in a VPC (virus producing cell); and blocking a virus infection by inactivating an infectivity of a released virions from the VPC; or (b) expressing a glycoprotein or a mutant thereof in the VPC; blocking the virus infection by preventing binding of the released virions to a target cell; inactivating infectivity of the released virions; and targeting a viral infection. Other embodiments relate to (1) a broad-spectrum anti-viral product comprising: a vector expressing a glycoprotein or a mutant thereof in a VPC; and blocking a virus infection by inactivating infectivity of a released virion from the VPC; and (2) a vaccine comprising a viral particle is configured to a live attenuated or an inactivated or a non-infectious, wherein the viral particle are produced in a VPC. | 2020-10-08 |
20200316191 | METHODS AND COMPOSITIONS FOR TREATING AND PREVENTING HIV - Methods and compositions are provided that can be used to vaccinate against and treat HIV. Specifically contemplated are vaccine compositions and methods of using these compositions treat HIV in patients. Aspects of the disclosure relate to an anti-CD40 antibody-HIV antigen fusion protein comprising (i) an anti-CD40 heavy chain (HCD40)-HIV antigen (Ag) fusion protein comprising the formula: HCD40-Ag, wherein Ag is a polypeptide with at least 80% sequence identity to SEQ ID NO:1; and (ii) an anti-CD40 light chain (LCD40). | 2020-10-08 |
20200316192 | Methods Of Vaccine Administration - This invention relates to a method of treating a dog for canine diseases comprising administering to the dog therapeutically effective amounts of a vaccine, wherein the vaccine comprises viral antigens, a bacterin, or both, and wherein the vaccine is administered subcutaneously or orally according to the schedules provided herein. | 2020-10-08 |
20200316193 | GENETICALLY STABLE RECOMBINANT MODIFIED VACCINIA ANKARA (RMVA) VACCINES AND METHODS OF PREPARATION THEREOF - A vaccine comprising an immunologically effective amount of recombinant modified vaccinia Ankara (rMVA) virus which is genetically stable after serial passage and produced by a) constructing a transfer plasmid vector comprising a modified H5 (mH5) promoter operably linked to a DNA sequence encoding a heterologous foreign protein antigen, wherein the expression of said DNA sequence is under the control of the mH5 promoter; b) generating rMVA virus by transfecting one or more plasmid vectors obtained from step a) into wild type MVA virus; c) identifying rMVA virus expressing one or more heterologous foreign protein antigens using one or more selection methods for serial passage; d) conducting serial passage; e) expanding an rMVA virus strain identified by step d); and f) purifying the rMVA viruses from step e) to form the vaccine. One embodiment is directed to a fusion cytomegalovirus (CMV) protein antigen comprising a nucleotide sequence encoding two or more antigenic portions of Immediate-Early Gene-1 or Immediate-Early Gene-2 (IEfusion), wherein the antigenic portions elicit an immune response when expressed by a vaccine. | 2020-10-08 |
20200316194 | Treatment of Infection - The invention relates to compositions including a substance useful as an adjuvant for potentiating an immune response, and methods of using the composition in individuals with infections of tissue within or adjacent to a transformation zone, such as the transformation zone of the cervix or anal canal. | 2020-10-08 |
20200316195 | TfR SELECTIVE BINDING COMPOUNDS AND RELATED METHODS - The present invention relates to peptides that bind with high specificity and which functionally interact with the transferrin receptor (“TfR”) and which may be used in making molecular vehicles that carry biomolecules across membranes, including, e.g., across the blood brain barrier or the gastrointestinal tract. TfR specific binding moieties may also be used alone or as components in specific molecules that target the transferrin/transferrin receptor transport system. The invention relates more specifically to VNAR single chain antibodies derived from nurse shark that bind to TfR, compounds and compositions comprising a TfR specific VNAR binding moiety, methods for preparing them, diagnostic and therapeutic methods of use in vitro or in vivo, e.g., to diagnose, treat and/or prevent a pathological condition, disorder or disease in which it is beneficial to deliver a heterologous biomolecule across the blood brain barrier by association with a TfR specific VNAR binding moiety. Other uses for TfR specific VNAR binding moieties of the invention include, e.g., regulating the interaction of iron-charged transferrin with TfR (receptor cycling or cell surface presentation), such as may be therapeutic in treatment of certain cancer cells and tumors of various tissue types. | 2020-10-08 |
20200316196 | STABILIZING EXCIPIENTS FOR THERAPEUTIC PROTEIN FORMULATIONS - The invention encompasses injectable therapeutic formulations for injection into patients in need thereof, wherein the injectable formulations are injected using a medical device having a hydrophobic surface; the injectable therapeutic formulation comprises a therapeutic protein and a stabilizing excipient that protects the therapeutic protein from forming particulates or aggregates in the presence of the hydrophobic surface. Also included are methods for reducing particulates or aggregates by using such injectable therapeutic formulations in medical devices having hydrophobic surfaces. | 2020-10-08 |
20200316197 | Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses in Combination with Bortezomib and Dexamethasone - The present invention relates to clinically proven subcutaneous pharmaceutical compositions comprising anti-CD38 antibodies and methods of their uses in combination with bortezomib and dexamethasone. | 2020-10-08 |
20200316198 | RECOMBINANT MVA OR MVADELE3L EXPRESSING HUMAN FLT3L AND USE THEREOF AS IMMUNO-THERAPEUTIC AGENTS AGAINST SOLID TUMORS - The present invention relates generally to the fields of oncology, virology and immunotherapy. More particularly, it concerns the use of a recombinant modified vaccinia Ankara (MVA) virus comprising an MVA harboring a human Fms-like tyrosine kinase 3 ligand (hFlt3L) (MVA-hFtl3L). The foregoing vaccinia Ankara (MVA) virus can be delivered to tumor cells of a subject afflicted with a malignant solid tumor, to treat the tumor. In a related aspect, the present disclosure concerns a recombinant modified vaccinia Ankara virus with deletion of vaccinia virulence factor E3 (MV At.E3L) modified to express human Fins-like 5 tyrosine kinase 3 ligand (hFlt3L) isolated, suitable for use as an immunotherapeutic agent against a malignant solid tumor. | 2020-10-08 |
20200316199 | NOVEL ANTI-LAM AND ANTI-PIM6/LAM MONOCLONAL ANTIBODIES FOR DIAGNOSIS AND TREATMENT OF MYCOBACTERIUM TUBERCULOSIS INFECTIONS - The present invention broadly provides different compositions, kits, vectors, and methods including monoclonal antibodies directed to epitopes found within lipoarabinomannan (LAM) and phosphatidyl-myo-inositol mannoside 6 (PIM6) for the diagnosis and treatment of | 2020-10-08 |
20200316200 | DEVICES AND PROCESSES FOR CHERENKOV-ACTIVATED NUCLEAR-TARGETED PHOTODYNAMIC THERAPY - Devices, materials, compounds, systems, and processes for Cherenkov-Activated Nuclear-Targeted Photodynamic Therapy that involves generating Cherenkov light within the tissue of a target volume and using this light to activate photosensitizing material that is located in the nucleus of cells of the target volume. | 2020-10-08 |
20200316201 | COMPOSITIONS AND METHODS FOR INHIBITION OF HAO1 (HYDROXYACID OXIDASE 1 (GLYCOLATE OXIDASE)) GENE EXPRESSION - The invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the HAO1 gene, and methods of using such RNAi agents to inhibit expression of HAO1 and methods of treating subjects having, e.g., PH1. | 2020-10-08 |
20200316202 | Methods for Prevention and Treatment of Cancers - This application discloses methods for prevention and treatment of cancers. Due to the larger size of human white blood cells compared to red blood cells, a decrease in the diameter of a part of a blood vessel can block the flow of white blood cells while allowing the flow of red blood cells. As a result, in tissues with such reduction in the diameter of blood vessels, there are areas where red blood cells are present, while there is a lack of white blood cells to fight the parasites and cancer cells. Therefore, cancer cells and other parasites can reside in such areas, replicate, and develop into diseases. | 2020-10-08 |
20200316203 | Methods for Prevention and Treatment of Infectious Diseases - This application discloses methods for prevention and treatment of infectious diseases. Due to the larger size of human white blood cells compared to red blood cells, a decrease in the diameter of a part of a blood vessel can block the flow of white blood cells while allowing the flow of red blood cells. As a result, in tissues with such reduction in the diameter of blood vessels, there are areas where red blood cells are present, while there is a lack of white blood cells to fight the parasites. Therefore, parasites can reside in such areas, replicate, and develop into infections. | 2020-10-08 |
20200316204 | PROPYLENE GLYCOL-CONTAINING PEPTIDE FORMULATIONS WHICH ARE OPTIMAL FOR PRODUCTION AND FOR USE IN INJECTION DEVICES - The present invention relates to pharmaceutical formulations comprising a peptide and propylene glycol, to methods of preparing such formulations, and to uses of such formulations in the treatment of diseases and conditions for which use of the peptide contained in such formulations is indicated. The present invention further relates to methods for reducing the clogging of injection devices by a peptide formulation and for reducing deposits on production equipment during production of a peptide formulation. | 2020-10-08 |
20200316205 | Solid Solution Compositions and Use in Severe Pain - The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a severe pain in an individual using such pharmaceutical compositions. | 2020-10-08 |
20200316206 | SALICYLIC ACID GEL - A concentrated salicylic acid gel comprising salicylic acid and a stabilizer compound, wherein the salicylic acid comprises at least 30 wt % of the total weight of the gel. | 2020-10-08 |
20200316207 | POLYMERIC BILE ACID NANOPARTICLES AS ANTI-INFLAMMATORY AGENTS - Polymeric poly(bile acid) (pBA) nanoparticles have enhanced avidity and affinity to bile acid receptors and are effective anti-inflammatory agents. Oral delivery results in local accumulation and retention in the pancreas, liver, and colon as well as in systemic delivery of the nanoparticles. The nanoparticles are effective in alleviating inflammation and are useful as anti-inflammatory agents to treat inflammatory diseases of the organs. The nanoparticles provide a therapeutic and prophylactic benefit via the TGR5 pathway when used alone, or a more than additive benefit when used in combination with immunosuppressant(s). The nanoparticles induce immune tolerance in autoimmune diseases and are useful therapeutics for treating inflammatory and autoimmune diseases. | 2020-10-08 |
20200316208 | MECHANICAL PROCESSING OF BIOPOLYMERS - Embodiments described herein generally relate to methods of processing of biopolymers and applications utilizing these biopolymers. | 2020-10-08 |
20200316209 | PEPTIDE DERIVATIVES HAVING NOVEL LINKAGE STRUCTURES - A compound comprising at least one looped peptide structure attached via at least one alkylamino linkage to a scaffold. Preferably the looped peptide structure is a Bicycle structure comprising two peptide loops attached to the scaffold via two alkylamino linkages and one thioether linkage, one of the linkages being common to both loops. Also provided is a method of making a compound comprising at least one looped peptide structure attached via at least one alkylamino linkages to a scaffold, the method comprising: providing a peptide having at least two residues selected from cysteine, diaminopropionic acid, β-N-Alkyldiaminopropionic acid and β-N-Alkyldiaminopropionic acid, provided that at least one of the residues is diaminopropionic acid, β-N-Alkyldiaminopropionic acid and β-N-Alkyldiaminopropionic acid, providing a scaffold molecule having at least two reactive sites for forming alkylamino or thioether linkages with the said at least two residues; and forming said linkages between the peptide and the scaffold molecule. | 2020-10-08 |
20200316210 | Cell-Penetrating Peptides For Antisense Delivery - Provided herein are oligonucleotides, cell penetrating peptides, and peptide-oligonucleotide-conjugates. Also provided herein are methods of treating a muscle disease, a viral infection, or a bacterial infection in a subject in need thereof, comprising administering to the subject oligonucleotides, peptides, and peptide-oligonucleotide-conjugates described herein. | 2020-10-08 |
20200316211 | LOCALLY ACTING TOLL-LIKE RECEPTOR 7 (TLR7) AND/OR TLR8 AGONIST IMMUNOTHERAPY COMPOUNDS AND THEIR USES - Provided in the present disclosure are immunotherapy compounds, pharmaceutical compositions thereof and their use, wherein the immunotherapy compounds, upon local administration, form depots inducing cell mediated immune response while mitigating a systemic proinflammatory immune response. | 2020-10-08 |
20200316212 | METHODS OF TREATING CANCER USING COMPOUNDS CONTAINING A VASCULAR DISRUPTING AGENT - The present invention relates to prodrugs of vascular disrupting agents comprising a vascular disrupting agent (VDA) associated with a MMP proteolytic cleavage site and to the use of such prodrugs in the targeted treatment of cancer. | 2020-10-08 |
20200316213 | MACROMOLECULAR PLATFORM FOR TARGETING SCAVENGER RECEPTOR A1 - The present invention is directed to a polymer platform comprising poly(L-lysine succinylated) which specifically targets scavenger receptor A1. This platform may be used to conjugate different types of drugs to the polymer for treatment of specific diseases or conditions in a patient. The resulting conjugates display moderate stability or controlled drug release of about 3-80 hours in plasma, and allow delivery and release of drugs and other therapeutic moieties to tissues/cells that express scavenger receptor A1 in a controlled manner. | 2020-10-08 |
20200316214 | ANTI-CANCER COMPOUNDS AND CONJUGATES THEREOF - Disclosed herein are compounds, drug-conjugates thereof, methods of preparing drug-conjugates, and uses thereof. Also disclosed are pharmaceutical compositions and methods of treatment. The compounds and drug-conjugates disclosed herein can be used to treat a variety of conditions, diseases and ailments such as bladder cancer, breast cancer, colon cancer, rectal cancer, endometrial cancer, kidney cancer, lung cancer, melanoma, non-Hodgkin lymphoma, glioblastoma, pancreatic cancer, prostate cancer, and thyroid cancer. | 2020-10-08 |
20200316215 | ANTI-SEZ6 ANTIBODY DRUG CONJUGATES AND METHODS OF USE - Provided are novel anti-SEZ6 antibodies and antibody drug conjugates, and methods of using such anti-SEZ6 antibodies and antibody dmg conjugates to treat cancer. | 2020-10-08 |
20200316216 | COMBINATIONS AND MODES OF ADMINISTRATION OF THERAPEUTIC AGENTS AND COMBINATION THERAPY - The present invention provides combination therapy methods of treating proliferative diseases (such as cancer) comprising a first therapy comprising administering to an individual an effective amount of a taxane in a nanoparticle composition, and a second therapy which may include, for example, radiation, surgery, administration of chemotherapeutic agents (such as an anti-VEGF antibody), or combinations thereof. Also provided are methods of administering to an individual a drug taxane in a nanoparticle composition based on a metronomic dosing regime. | 2020-10-08 |
20200316217 | ENGINEERED LIGANDS AND USES THEREOF - Described herein are engineered ligand that binds a cell surface receptor (e.g., GPCR), with improved affinity, potency, and specificity. By conjugating a sub-optimal ligand for a cell surface receptor (e.g., GPCR) to a targeting molecule that binds an epitope (natural or exogenous epitope) in the extracellular portion of the cell surface receptor (e.g., GPCR), the affinity, potency, and/or specificity of the sub-optimal ligand is enhanced. | 2020-10-08 |
20200316218 | CELL SURFACE CONJUGATES AND RELATED CELL COMPOSITIONS AND METHODS - Provided herein are cell surface conjugates containing a cell surface molecule and at least one agent, such as at least one affinity tag, and engineered cells expressing such cell surface conjugates. In some embodiments, the cell surface molecule does not contain an intracellular signaling domain or is not capable of mediating intracellular signaling. In some embodiments, the cells engineered to contain the cell surface conjugate, such as T cells, further contain a genetically engineered recombinant receptor that specifically binds to antigens, such as a chimeric antigen receptor (CAR). Also provided are methods of detecting, identifying, selecting or targeting cells expressing the cell surface conjugates, such as in connection with methods of manufacturing engineered cells or in connection with administration of such cells to subjects, including methods of adoptive cell therapy. | 2020-10-08 |
20200316219 | METHODS OF TREATMENT USING ULTRASMALL NANOPARTICLES TO INDUCE CELL DEATH OF NUTRIENT-DEPRIVED CANCER CELLS VIA FERROPTOSIS - Described herein is a method of induced cell death via ferroptosis by nanoparticle ingestion. Moreover, the present disclosure describes the administration of high concentrations of ultrasmall nanoparticles at multiple times over the course of treatment in combination with a nutrient-depleted environment, thereby modulating cellular metabolic pathways to induce cell death by the mechanism ferroptosis. Ferroptosis involves iron, reactive oxygen species, and a synchronous mode of cell death execution. | 2020-10-08 |
20200316220 | ELECTROACTIVE SUPRAMOLECULAR POLYMERIC ASSEMBLIES, METHODS OF MAKING ELECTROACTIVE SUPRAMOLECULAR POLYMERIC ASSEMBLIES, AND METHODS OF USING ELECTROACTIVE SUPRAMOLECULAR POLYMERIC ASSEMBLIES - Embodiments of the present disclosure provide for electroactive supramolecular polymeric assemblies, methods of making electroactive supramolecular polymeric assemblies, methods of using electroactive supramolecular polymeric assemblies, and the like. | 2020-10-08 |
20200316221 | AAV CAPSID DESIGNS - The disclosure in some aspects relates to recombinant adeno-associated viruses having distinct tissue targeting capabilities. In some aspects, the disclosure relates to gene transfer methods using the recombinant adeno-associated viruses. In some aspects, the disclosure relates to isolated AAV capsid proteins and isolated nucleic acids encoding the same. | 2020-10-08 |
20200316222 | OPTIMIZED CLN1 GENES AND EXPRESSION CASSETTES AND THEIR USE - This invention relates to polynucleotides comprising a nucleotide sequence encoding a PPT1 polypeptide or a fragment thereof, vectors (viral or non-viral vectors) comprising the same, and methods of using the same for delivery of the open reading frame to a cell or a subject and to treat infantile neuronal lipofuscinosis (infantile Batten disease). The polynucleotides comprise an optimized CLN1 open reading frame. | 2020-10-08 |
20200316223 | ADENO-ASSOCIATED VIRUS COMPOSITIONS FOR PAH GENE TRANSFER AND METHODS OF USE THEREOF - Provided herein are adeno-associated virus (AAV) compositions that can express a phenylalanine hydroxylase (PAH) polypeptide in a cell, thereby restoring the PAH gene function. Also provided are methods of use of the AAV compositions, and packaging systems for making the AAV compositions. | 2020-10-08 |
20200316224 | Method and Kit for Treatment of Genetic Congenital Birth Defects - A method of treating a congenital birth defect includes detecting the presence of at least one mutated gene associated with a birth defect and injecting foreign genetic material containing at least one non-mutated version of the detected mutated gene into a patient, thereby promoting a desired therapeutic outcome in the patient. A kit for treating a congenital birth defect in a patient comprising normal genetic material tailored to treat the congenital birth defect and an injection device for providing the normal genetic material to the patient is also described. | 2020-10-08 |
20200316225 | Gene Therapy For Ocular Improvement - Targeted non-surgical administration of a nucleic acid formulation to the suprachoroidal space (SCS) of the eye of a human subject permits effective treatment of ocular disorders, including posterior ocular or choroidal maladies. In one embodiment, the method comprises inserting a hollow microneedle into the eye at an insertion site and infusing a nucleic acid formulation through the inserted microneedle and into the suprachoroidal space of the eye. The infused nucleic acid formulation flows within the suprachoroidal space away from the insertion site. In one embodiment, the fluid nucleic acid formulation comprises nucleic acid nanoparticles consisting of one molecule of nucleic acid. | 2020-10-08 |
20200316226 | ENGINEERED EXTRACELLULAR VESICLES FOR ENHANCED TISSUE DELIVERY - Several embodiments relate to engineered extracellular vesicles (EVs) using the membrane cloaking platform technology described herein, the cloaking imparting to the EVs enhanced delivery to tissues of interest, such as damaged or dysfunctional tissue. Several embodiments relate to engineering exosomes derived from cardiosphere-derived cells (CDCs) using the membrane cloaking platform technology described herein to confer enhanced tissue homing specificities, thereby leading to repair and regeneration at sites of injury. Uses of engineered EV compositions to treat diseases are also provided for in several embodiments. | 2020-10-08 |
20200316227 | IMAGING OF METASTATIC OR RECURRENT CANCER - The present disclosure relates to methods of administering [ | 2020-10-08 |
20200316228 | IMAGING OF METASTATIC OR RECURRENT CANCER - The present disclosure relates to methods of administering [ | 2020-10-08 |
20200316229 | COMPOUNDS AND COMPOSITIONS USEFUL AS RADIOTRACERS FOR IMAGING OF REACTIVE OXIDATIVE SPECIES - Provided herein are compounds and compositions useful for imaging, detecting, and/or diagnosing oxidative stress and/or a ROS modulated illness by detection of gamma radiation emitted by the compound, as well as intermediate compounds and methods useful to make the compounds and/or compositions, and methods of use thereof. | 2020-10-08 |
20200316230 | DEVICES AND METHODS FOR RADIOPHARMACEUTICAL SYNTHESIS - A device for synthesizing a radiotracer includes a microfluidic chip having a concentration module configured to concentrate and capture a radioactive reagent from a radioactive regent mixture, a reaction chamber in fluidic communication with the concentration module and configured to synthesize a radiotracer by reaction of the concentrated radioactive reagent and a radiotracer precursor therein, and a purification module in fluidic communication with the reactor chamber and configured to purify the synthesized radiotracer. The device also includes a heating means positioned in relation to the microfluidic chip for heating the microfluidic chip during evaporation and reaction; and a first valve fluidically coupled with the concentration module and the reaction chamber and a second valve fluidically coupled with the reaction chamber and the purification module for operably controlling transit of various substances or mixtures among the concentration module, the reaction chamber and the purification module. | 2020-10-08 |
20200316231 | Compositions And Methods For Imaging Immune Cells - The present disclosure provides immunes cells comprising a radiolabeled tracer useful in imaging tests such as positron emission topography (PET)/computed tomography (CT) scans. The present disclosure further includes engineered cells comprising a chimeric antigen receptor (CAR) further comprising a nucleic acid molecule comprising a ligand binding domain capable of binding to radiolabeled tracer. This disclosure also includes methods for assessing the efficacy or toxicity of an adoptive cell therapy in a subject, methods for detecting the quantity of engineered T cells in a subject, methods for monitoring an immunotherapy treatment in a subject and methods of imaging engineered T cells in a subject. In some embodiments, the radiolabeled tracer is [ | 2020-10-08 |
20200316232 | RADIOLABELED COMPOUNDS - The present invention relates to radiolabeled compounds of formula I | 2020-10-08 |
20200316233 | RADIOPHARMACEUTICALS AND METHODS OF USE THEREOF - Targeted pharmaceuticals, particularly targeted radiopharmaceuticals, are provided which possess extended tumor retention time. | 2020-10-08 |
20200316234 | PIPETTE CAROUSEL WITH GERMICIDAL LAMP - An apparatus for decontaminating and storing lab instruments such as pipettes. A carousel feature of the apparatus provides convenient access and allows multiple items to be decontaminated at the same time. The ultraviolet lamp directs UV radiation to surface contaminations of the instruments and effectively eliminates various microorganisms. | 2020-10-08 |
20200316235 | POWDER STERILIZATION METHOD AND DEVICE - A powder sterilization method for sterilizing powder, in particular an active pharmaceutical ingredient in powder form or food in powder form, using fluid vapor, in particular steam. According to the invention, the fluid vapor is applied to the powder in an evacuated treatment chamber ( | 2020-10-08 |
20200316236 | METHOD AND DEVICE FOR A POLYESTER STERILIZATION PROCESS - Described herein are packages for orienting and cooling polyesters during a sterilization process, and containers for storing, transporting, and cooling the package. Also described herein are methods of sterilizing polyesters. | 2020-10-08 |
20200316237 | Sanitization Assembly, Shelf for Furnishing Element with Sanitization Assembly and Furnishing Element with Sanitization Assembly - Described herein is a sanitization assembly including: a sanitization device, such as for example a photocatalytic device or ionizer or the like; and a containment element. The sanitization device is received in the containment element, and the containment element includes a box-shaped, box-like containment body. The box-like containment body includes side containment body surfaces and has dimensions in the width and thickness thereof that are substantially the same as those of a panel or rack or shelf of a furnishing element that includes side shelf surfaces. The box-like containment body can be assembled on the panel or rack or shelf, thus being continuous with the panel or rack or shelf. The side shelf surfaces substantially continue in the side containment body surfaces. | 2020-10-08 |
20200316238 | MOBILE DEVICES HAVING DISINFECTION LIGHT SOURCES - The present invention relates to mobile devices for disinfecting an object. The mobile device includes: one or more light sources for generating a disinfection light; a display; one or more processors coupled to the one or more light sources and display; and a non-transitory computer-readable medium comprising one or more sequences of instructions which, when executed by the one or more processors, causes steps to be performed including: determining a required dosage of the disinfection light; determining an exposure time of the disinfection light that corresponds to the required dosage of the disinfection light; illuminating the disinfection light on the surface; and displaying a disinfection map on the display to report a result of a disinfection process performed by the illumination of the disinfection light. | 2020-10-08 |
20200316239 | PLASMA STERILIZATION AND DRYING SYSTEM AND METHODS - A system and methods for sterilizing and drying contaminated articles, particularly medical articles, and more particularly the hollow internal areas of medical instruments or lumens of medical endoscopes. The system includes a plasma generator having an electrode, a shield, and a dielectric gap between the electrode and the shield. A source of electrical power connected to the plasma generator applies an electrode energy density between the electrode and the shield. A source of a sterilizing gas precursor provides a flow of the sterilizing gas precursor through the plasma generator to generate a plasma, thereby forming a sterilizing gas including acidic and/or oxidizing species. The contaminated article is exposed to the sterilizing gas for a time sufficient to achieve a desired degree of sterilization. A turbulent flow of a drying gas is used to dry the contaminated article alternately with the exposure of the contaminated article to the sterilizing gas. | 2020-10-08 |
20200316240 | PROCESS AND PLANT FOR MANUFACTURING AND TREATING CONTAINERS - Disclosed is a process for treating at least one hollow body made of thermoplastic material, such as a preform or a cap, the treatment process successively including at least the following steps: a first step, consisting in treating at least the inside of the hollow body using hydrogen peroxide; a second step, consisting in heating the hollow body; a third step, consisting in treating the hollow body with plasma in order to reduce the concentration of hydrogen peroxide residues. Also disclosed is a plant for manufacturing containers in which the process is carried out in particular by way of a unit for the plasma treatment of the preforms. | 2020-10-08 |
20200316241 | DEODORANT DISPERSION, DEODORANT-CONTAINING PROCESSING SOLUTION, AND METHOD FOR PRODUCING DEODORANT PRODUCT - The deodorant dispersion of the present invention includes (A) two or more powdery inorganic chemical adsorbents, (B) a dispersing agent, and (C) a dispersion medium, a content proportion of the component (A) is in a range from 10% to 30% by mass based on a total of the deodorant dispersion, a content proportion of the component (B) is in a range from 1% to 10% by mass based on a total of the deodorant dispersion, and a median particle diameter of a dispersoid is in a range from 0.1 μm to 0.4 μm. A gas adsorption capacity of the component (A) is preferably 25 mL/g or more. | 2020-10-08 |
20200316242 | DEVICE FOR EVAPORATING VOLATILE SUBSTANCES - A device for evaporating volatile substances including a solid body impregnated with volatile substances and a support for the solid body. The solid body includes a protrusion defining on the inside thereof a housing and the solid body includes a hole, inside of which the protrusion is placed, such that the device further includes a container to house a liquid which impregnates the solid body with volatile substances. The device allows the solid body to be correctly held in the support during the entire useful life thereof. Furthermore, due to the presence of the container with liquid, the user may know if the device is still evaporating the volatile substances correctly or if it must be replaced. | 2020-10-08 |
20200316243 | SCENTED NIGHT LIGHT - A scented plug-in night light provides a pedestal for variable, interchangeable thematic character statuettes, which are illuminated by the scented plug-in night light. The scented plug-in night light is optionally provided with a digital clock incorporated into the housing for the scented night light to turn on the night at specified times to illuminate a child's favorite thematic character, which can serve as an inducement for a child who is reluctant to observe bedtime. Thereafter the illuminated thematic character of the night light stays on to act as a safety night light during the selected duration of time, and an alarm for waking the child. | 2020-10-08 |
20200316244 | FLUID SYSTEM WITH INTEGRATED DISINFECTING OPTICS - A fluid disinfecting system includes a straight fluid directing conduit and a light source disposed on a side of the fluid directing conduit. The light source is operative to emit ultraviolet light into the fluid directing conduit, such that one or more cross sections of said fluid directing conduit are saturated with ultraviolet light. Any fluid passing through the fluid directing conduit is necessarily exposed to the ultraviolet light. | 2020-10-08 |
20200316245 | Biodegradable Absorbent Articles - A biodegradable, disposable absorbent article, such as a diaper, having a non-woven inner layer of natural fibers and a non-woven outer layer of natural fibers and a treatment applied to at least one surface thereof. The treatment includes at least one compound selected from the group consisting of waxes, urethanes, silicones, fluorocarbons, and non-fluorochemical repellants. The absorbent article has a core of natural fibers or fibrous material, and optionally polyacrylate superabsorbent particles, positioned between the inner layer and the outer layer. The article may contain polylactic acid films between the layers. | 2020-10-08 |
20200316246 | ABSORBENT ARTICLE WITH TACKIFIER-FREE ADHESIVE - Disposable absorbent articles assembled from a collection of components using an adhesive having an amorphous polyolefin composition with a random butane-α-olefin copolymer and a heterophase polyolefin copolymer composition with a first set of comonomer units and a second set of comonomer units, wherein the first set of comonomer units are propene. | 2020-10-08 |
20200316247 | MEDICAL MATERIAL PRODUCED USING COLLAGEN AND METHOD FOR PRODUCING SAME - Disclosed is a medical material manufactured using collagen and a method of manufacturing the same. The method includes (1) preparing collagen using distilled water as a solvent, (2) filling a syringe with the prepared collagen and then spinning the collagen through a syringe needle, (3) immediately immersing the spun collagen in a cross-linking solution, which is a mixture including therein a hyperosmotic agent and a cross-linking agent mixed with each other, (4) removing and then washing the collagen after cross-linking is completed, and (5) removing and then drying the collagen after the washing is completed. When the collagen is spun and processed into the form of a thread and the spun thread is then cross-linked, the cross-linked collagen thread has increased strength compared to before cross-linking, and the shape thereof is retained in an aqueous solution. | 2020-10-08 |
20200316248 | ALKYL CHITOSAN-GRAPHENE OXIDE COMPOSITE SPONGE AND PREPARATION METHOD AND APPLICATION THEREOF - The present invention relates to an alkyl chitosan-graphene oxide composite sponge and preparation method and application thereof. The alkyl chitosan-graphene oxide composite sponge provided by the present invention includes alkyl chitosan and graphene oxide absorbed on the alkyl chitosan, and the adsorbing capacity of the graphene oxide is 3-28 wt. %. In the present invention, alkyl chitosan is used as a matrix to combine graphene oxide and alkyl chitosan; the obtained composite sponge has excellent hemostatic performance and blood absorption capacity. Results of embodiments indicate that the in-vitro whole blood coagulation time is less than 58 s, the hemostasis time of a rabbit femoral artery hemorrhage model is less than 155 s, the hemorrhage mass is less than 5.4 g, and the hemostatic effect is superior to a pure alkyl chitosan sponge or graphene oxide powder when the composite sponge provided by the present invention is used for hemostasis. | 2020-10-08 |
20200316249 | BIOCOMPATIBLE HYDROGEL TREATMENTS FOR RETINAL DETACHMENT - Provided herein are in vivo gelling ophthalmic pre-formulations forming a biocompatible retinal patch comprising at least one nucleophilic compound or monomer unit, at least one electrophilic compound or monomer unit, and optionally a therapeutic agent and/or viscosity enhancer. In some embodiments, the retinal patch at least partially adheres to the site of a retinal tear. Also provided herein are methods of treating retinal detachment by delivering an in vivo gelling ophthalmic pre-formulation to the site of a retinal tear in human eye, wherein the in vivo gelling ophthalmic pre-formulation forms a retinal patch. | 2020-10-08 |
20200316250 | BONE IMPLANT - The invention relates to the field of medicine and medical technology, namely to bone implants, and can be used in surgery, orthopedics, dentistry. Bone implants made of dense tough fibrous or fine-crystal silicate mineral aggregate or rock, jade, have high strength, resistance to crack formation, biological compatibility and the ability to integrate into bone tissue. The technical result—expanding the field of medical devices for implantation into bone tissue. | 2020-10-08 |
20200316251 | SOFT HYDROPHOBIC ACRYLIC MATERIALS - Soft hydrophobic acrylic materials with improved resistance to fluid diffusion and suitable mechanical properties that allow deformation upon application of force are disclosed. The acrylic materials are particularly suitable for use in fluid-based accommodating intraocular lenses and comprises combination of a perfluoro-substituted alkyl (meth)acrylate and an alkyl (meth)acrylate, and a cross-linking agent. | 2020-10-08 |
20200316252 | 3D PRINTABLE BIO GEL AND METHOD OF USE - Collagen compositions, methods for preparing those collagen compositions, and 3D constructs formed from those collagen compositions are provided. In particular, methods of isolating collagen that exhibits an enhanced rate of gelling, such collagen compositions, and 3D constructs formed from such collagen compositions are provided. | 2020-10-08 |
20200316253 | IMPLANTABLE SCAFFOLDS FOR TREATMENT OF SINUSITIS - This disclosure describes, inter alia, materials, devices, kits and methods that may be used to treat chronic sinusitis. More specifically, a drug-eluting scaffold is implanted in the middle meatus to treat chronic sinusitis for weeks to months. | 2020-10-08 |
20200316254 | THREE-DIMENSIONAL BIOPRINTING OF CARDIAC PATCH WITH ANISOTROPIC AND PERFUSABLE ARCHITECTURE - A cardiac patch for treatment of a mammalian heart including perfusable vessels embedded integratedly between two layers of anisotropically oriented myocardial fibers. The cardiac patch is made using a dual 3D bioprinting technique using stereolithography to form an anisotropic construct and extrusion printing to form perfusion vessels. A nutrient and oxygen containing media can be provided within the perfusion vessels for growth of cells in the cardiac patch. The technique permits larger patches to be made for the treatment of cardiac damage in both small and large mammalian hearts. | 2020-10-08 |
20200316255 | HUMAN CELL-DEPOSITED EXTRACELLULAR MATRIX COATINGS FOR TEXTILES AND FIBERS - A process of forming a coated textile includes culturing human cells on a fiber of a textile such that the human cells produce and deposit human extracellular matrix (hECM) on the textile. The process also includes removing the human cells from the hECM to provide the coated textile of the textile and a coating comprising a residual of the hECM produced and deposited by the human cells on the textile during the culturing. A coated textile includes a textile and a coating on the textile. The coating includes hECM in a cell-deposited state in the coating. A solid-state bioreactor composition includes a poly(glycerol sebacate) (PGS) adduct. The PGS adduct includes PGS and a promoting factor or a promoting factor precursor. Another method includes implanting a coated textile in a human. The coated textile is an autograft. The coating includes hECM deposited by human cells from the human. | 2020-10-08 |
20200316256 | REINFORCED TISSUE GRAFT - One aspect of the present disclosure can include a biocompatible tissue graft. The graft can include an extracellular matrix (ECM) patch or strip and at least one fiber stitched into the ECM patch or strip in a peripheral reinforcement pattern. The at least one fiber can have opposing terminal ends. The at least one fiber can mitigate tearing and/or improve fixation retention of the ECM patch or strip. The at least one fiber can comprise a plurality of interconnected stitches. The opposing terminal ends of the at least one fiber can be stitched together to form a continuous stitching construction. | 2020-10-08 |
20200316257 | QUILTED IMPLANTABLE GRAFT - Described are embodiments of a multilaminate or multiple layer implantable surgical graft comprising remodelable collagenous sheet material, the graft including one or more interweaving members to stitch together the graft to help prevent the layers from delaminating or separating during handling and the initial stages of remodeling. The interweaving members may comprise lines of suture, thread, individual stitches, strips of material, etc. that are woven through the layers of biomaterial in a desired pattern. In one embodiment, the interweaving members comprise a pharmacologically active substance, such as a drug, growth factors, etc. to elicit a desired biological response in the host tissue. In another embodiment, the graft further comprises a reinforcing material, such as a synthetic mesh, within the layers of remodelable biomaterial and stitched together by one or more interweaving members. | 2020-10-08 |
20200316258 | GROWTH FACTOR TRANSDUCED CELL-LOADED CERAMIC SCAFFOLD FOR BONE REGENERATION AND REPAIR - Disclosed herein are methods of regional gene-therapy with growth-factor transduced cells, in bone graft scenarios. In embodiments, the methods comprise use of 3D printed scaffolds. | 2020-10-08 |
20200316259 | Method of making an osteoconductive polymer article and an osteoconductive polymer article thus made - The disclosure relates to methods of making an osteoconductive polymer article for use as an orthopedic implant comprises steps of forming an article from a biocompatible, non-biodegradable polymer, the article comprising a non-flat surface with roughness Ra of at least 5 μm; providing a dispersion of bioactive ceramic particles of particle size at most 10 μm in a first solvent comprising a solvent for the polymer; coating at least the non-flat surface with the dispersion in at least one step; and rinsing the coated article with a second solvent being a non-solvent for the polymer to substantially remove the first solvent. Further disclosed is an osteoconductive polymer article for use as an orthopedic implant, which article is made from a biocompatible, non-biodegradable polymer and comprises a non-flat surface with roughness Ra of at least 5 μm, wherein bioactive ceramic particles of particle size at most 10 μm are partly embedded in the polymer at the surface of the article. The methods exhibit benefits in ease of modifying a surface layer with bioactive particles, applying mild conditions and not requiring use of further additives or post-treatments, or without significantly affecting bulk polymer properties, and result in an orthopedic implant article having particles adhering to the surface while still being accessible for interaction with surrounding tissue or fluid. | 2020-10-08 |
20200316260 | INJECTABLE GEL PRODUCT - A method of producing an injectable gel product is provided, comprising (a) cross-linking a first glycosaminoglycan (GAG) with a first crosslinking agent to produce a gel, wherein the charging ratio of crosslinking agent to disaccharide unit is below 0.15; (b) preparing particles of the gel; (c) mixing the glycosaminoglycan (GAG) gel particles with a second GAG to provide a mixture; (d) cross-linking the mixture with a second crosslinking agent to obtain cross-linking between the GAGs of the second, outer phase, thereby providing a gel having a first, inner phase of the cross-linked GAG gel particles, embedded in a gel of the second GAG outer phase; and (e) preparing injectable particles, each such particle containing a plurality of the cross-linked GAG gel particles of the first, inner phase. An injectable gel product, an aqueous composition, and a pre-filled syringe as also provided. | 2020-10-08 |
20200316261 | HYDROGELS BASED ON BLOOD PLASMA COMPONENTS, PROCESS AND USES THEREOF - The present disclosure relates to bioactive hydrogels derived from human blood plasma. More particularly, the disclosure relates to multifunctional materials for cell encapsulation, cell culture platforms, medical treatment apparatus and methods, more particularly, hydrogels derived from human blood components and technologies for use of such materials in research, biomedical treatment, biotech and pharmaceutical industry. The disclosure further relates to 3D printable scaffolds, sponges, foams, fibers, particles, capsules, membranes and injectable systems comprising said hydrogel. Additionally, this disclosure allows for the controlled placement of biologically active components that may be delivered by the hydrogel compositions. | 2020-10-08 |
20200316262 | EXTENDED RELEASE IMMUNOMODULATORY IMPLANT TO FACILITATE BONE MORPHOGENESIS - An extended release immunomodulatory implant operatively arranged to facilitate bone morphogenesis, including an inner portion including at least one growth factor, a first layer including at least one of one or more interleukins and capsaicin, and a second layer including an antigen operatively arranged to activate an innate immune system. | 2020-10-08 |
20200316263 | COMPOSITE DURA SUBSTITUTE IMPLANT - A composite dura substitute implant for implantation at a dura defect site having a porous layer that provides an osteoconductive scaffold for bony ingrowth, a porous layer that provides a scaffold for regeneration of collagen at a dura surface, and an intervening layer for preventing cerebrospinal leakage is disclosed. The composite dura substitute implant facilitates regeneration of dura mater and promotes osteointegration with bony tissue. Methods of manufacturing such an implant and methods of treatment using such composite dura substitute implants are further disclosed. | 2020-10-08 |
20200316264 | RADIOPAQUE MATERIAL AND COMPOSITIONS AND DEVICES INCLUDING THE SAME - A radiopaque filler material contains a mixture of a first radiopaque material and a second radiopaque material different from the first radiopaque material. The radiopaque filler material may be dispersed in a polymeric material. The polymeric material may be used to prepare a medical device or a part thereof. The polymeric material containing the radiopaque filler material exhibits a level of radiopacity that is substantially even across varying imaging energy levels. | 2020-10-08 |
20200316265 | MULTIPHASE GEL - Disclosed are hydrogels polymerized with or around a solid biofunctional moiety, biodegradable or permanent, designed to be implantable in a mammalian body, intended to block or mitigate the formation of tissue adhesions, and intended to aid in functional healing. The hydrogels of the present invention are characterized by comprising multiphasic structural elements: a) at least one gel phase, b) at least one solid phase, c) optional polymeric chains connecting gel and solid phases, d) optional shape designs that provide for an interpenetrating geometry between gels and solids, e) optional shape designs that enhance a tissue-hydrogel interface, and f) optional shape designs that provide a biofunctional aspect. The hydrophobicity of the various phases is chosen to reduce tissue adhesion and enhance tissue healing. The morphology of the polymers comprising the gel phase is typically of high molecular weight and has morphology that encourages entanglement. Useful polymeric structures include branching chains, comb or brush, and dendritic morphologies. | 2020-10-08 |
20200316266 | SILICON-REINFORCED VEIN STENT - The silicon-reinforced stent is a specially designed stent structured and arranged with a silicon coating over the metal stent structure to maintain a firmer and longer lasting stent. The silicon may be similar to Vaseline and may also prevent plaque from further accumulating in the vein. Additionally, the silicon coating will help prevent the edges of the metal structure from collapsing, thereby ensuring that if the stent moves or comes out, the movement will cause less damage. | 2020-10-08 |
20200316267 | HAEMOSTATIC DEVICE - A bioresorbable haemostatic foam sponge for adhering to a wound. The sponge has a tissue-contacting surface divided into a plurality of closely-spaced tissue contacting elements. Also disclosed are methods for forming the haemostatic sponge and methods of using the sponge. | 2020-10-08 |
20200316268 | IMMOBILISING BIOLOGICAL ENTITIES - There is provided inter alia a solid object having a surface comprising a layered coating of cationic and anionic polymer, wherein the outer coating layer is a layer comprising cationic polymer to which is covalently bound an anticoagulant entity; and wherein the anionic polymer is characterized by having (a) a total molecular weight of 20 kDa-650 kDa; and (b) a solution charge density of ≤4 μeq/g. | 2020-10-08 |
20200316269 | STIMULATION OF CARTILAGE FORMATION USING REDUCED PRESSURE TREATMENT - System and methods for stimulating cartilage formation at a first tissue site through a second tissue site is presented. The system includes a fluid source for supplying a therapeutic solution, a reduced pressure source for supplying reduced pressure, a fluid delivery manifold for deploying adjacent the first tissue site, and a vacuum manifold for deploying within the second tissue site. The fluid delivery manifold extends between a proximal end fluidly coupled to the fluid supply and a distal end having at least one aperture for delivering the therapeutic solution to the defect adjacent the articulating surface of the first tissue site. The vacuum manifold extends between a proximal end fluidly coupled to the reduced pressure source and a distal end having at least one aperture for delivering the reduced pressure to the first tissue site adjacent the opposing surface of the first tissue site. | 2020-10-08 |
20200316270 | Skin Treatment Device for Balancing pH Value of Skin - Various aspects of a skin treatment device and a method to cleanse and balance pH value of skin are disclosed herein. In accordance with an embodiment, the skin treatment device includes a nozzle to be directed into contact with the skin of a subject. A vacuum pump may be operably coupled to the nozzle for generating a suction force of the nozzle to evacuate impurities from the skin. A liquid replenishing assembly may be operably coupled to the nozzle for atomizing liquid at a pre-defined pH value. The liquid from the liquid replenishing assembly may pass into the nozzle based on the pre-defined pH value. The first control valve may be connected to an outlet of the vacuum pump and an outlet of the liquid replenishing assembly for communication with the nozzle. | 2020-10-08 |
20200316271 | APPARATUS FOR WOUND THERAPY - A wound therapy apparatus is disclosed that includes a wound interface securable to a skin surface around a wound bed to form an enclosed space over the wound bed that is fluid-tight. The wound therapy apparatus-may include a dressing engaged with the wound interface to contact the wound bed. A spacer may be disposed within the enclosed space proximal of the dressing to define a plenum between portions of the wound interface and a proximal side of the dressing. Gas within the enclosed space may have an O | 2020-10-08 |
20200316272 | SUCTION-BASED MEDICAL DRESSING AND METHOD OF DERMAL IRRIGATION - A suction-based medical dressing assembly and method of dermal irrigation provides a flexible tube that is fluidly coupled to at least two bifurcated tube portions defined by a plurality of apertures. The tube has a proximal end opening for discharging ambient fluid. The length of the bifurcated tube portions is surrounded by an absorbent gauze material covered substantially with an occlusive sheet material, and having an adhesive strip thereon. A vacuum assembly creates a negative pressure in the tubes. The ambient fluid is absorbed by the absorbent material, and the negative pressure sucks the fluid through the apertures in the bifurcated tube portions for discharge through the opening in the tube. In operation, a patient applies the adhesive side of the occlusive device to the skin where liquid removal is desired and activates the vacuum-inducing source, thereby causing fluid runoff from the patient to be effectively removed for disposal. | 2020-10-08 |
20200316273 | MEDICAL GAUZE AND GAS FLOW ASSEMBLY AND METHOD OF APPLYING A MEDICAL GAUZE WITH GAS FLOW ON A WOUND - A medical gauze and gas flow assembly and method of applying a medical gauze with gas flow over a wound, provides a medical dressing cover that couples to a gas flow framing structure. The gas flow framing structure provides a flow of gas over a wound. A medical grade gauze material adheres to the lower surface of the medical dressing cover, so as to create spacing between the medical grade gauze material and the wound treatment area. The gas flow is directed between the medical grade gauze material and the wound treatment area. The gas flow vents to ambient though the gas permeable medical dressing cover. When degraded, the assembly is replaced or only the medical dressing cover and medical grade gauze material is replaced. The synergistic combination of a medical grade gauze material that is a gas permeable, with a gas flow structure that discharges gas over the wound enhances healing the wound. | 2020-10-08 |
20200316274 | SYSTEMS AND METHODS FOR EXPRESSION OF BREAST MILK - Disclosed herein are improved devices, systems, and methods for the expression and collection of breast milk, such as human breast milk. A breast shield assembly for expression of breast milk may comprise a breast interface and an actuatable assembly interface fluidly coupled with a tube, wherein the breast interface is configured to engage the breast and the actuatable assembly interface is configured to removably couple to an actuatable assembly. The breast shield assembly may comprise an enclosed fluid reservoir extending between the breast interface and the actuatable assembly interface, the fluid reservoir physically separated from the expressed breast milk and filled with a driving fluid comprising a liquid. The breast shield assembly may further comprise a fill port configured to allow addition or removal of the driving fluid to or from the fluid reservoir. | 2020-10-08 |
20200316275 | CANNULA FIXATION DEVICE - A medical fixation device which may include an elongate body with a proximal portion, a distal portion, and define a longitudinal axis extending therethrough. A first fixation member on the proximal portion of the elongate body and a second fixation member on the distal portion of the elongate body may also be included with the medical fixation device. The first fixation member and the second fixation member may each have a delivery configuration in which the first fixation member and the second fixation member are collapsed along the longitudinal axis, and an anchoring configuration in which the first fixation member and the second fixation member each extend radially outward from the elongate body, define a septal aperture therebetween, and each have a tip facing away from each other. | 2020-10-08 |
20200316276 | Sheath Device for Inserting a Catheter - A sheath device for inserting a catheter into a patient's body is described. The device has a first sheath with a proximal end and a distal end. When the device is used as intended, the distal end of the first sheath is provided for arrangement in the patient's body and the proximal end of the first sheath is provided for arrangement outside the patient's body. The first sheath comprises a tubular section and a sheath housing, which is disposed at the proximal end of the section and has a receiving channel for a strand-shaped body. The device solves the problem of reliably fixing a second sheath or a catheter with respect to the first sheath by providing a clamping element on the receiving channel for fixing a strand-shaped body in the receiving channel by way of clamping. | 2020-10-08 |
20200316277 | METHOD AND APPARATUS FOR LONG-TERM ASSISTING A LEFT VENTRICLE TO PUMP BLOOD - A method and apparatus for long-term assisting the left ventricle of a heart to pump blood is disclosed which includes at least one transluminally deliverable pump and a transluminally deliverable support structure which secures the at least one pump within the aorta for long-term use. | 2020-10-08 |
20200316278 | METHOD AND APPARATUS FOR LONG-TERM ASSISTING A LEFT VENTRICLE TO PUMP BLOOD - A method and apparatus for long-term assisting the left ventricle of a heart to pump blood is disclosed which includes at least one transluminally deliverable pump and a transluminally deliverable support structure which secures the at least one pump within the aorta for long-term use. | 2020-10-08 |
20200316279 | AIR MANAGEMENT DEVICE FOR DIALYSIS MACHINES - A dialysis system may include a dialysis machine (e.g., a peritoneal dialysis machine or a hemodialysis machine) for transferring a liquid to a patient via tubing. The dialysis system may include an air management device for filtering out air content from the liquid prior to transferring to the patient. The air management device may be a connector cap for use in a peritoneal dialysis system during a priming process. Alternatively, the air management device may be a drip chamber for use in a hemodialysis system. The air management device may include a vent. In addition, the air management device may include a movable element for sealing the vent. In addition, and/or alternatively, the air management device may include a reservoir for receiving an overflow of liquid. | 2020-10-08 |
20200316280 | PRIMING SENSOR FOR A MEDICAL FLUID DELIVERY SYSTEM - A priming sensor for a medical fluid delivery device is disclosed. In an example, the priming sensor includes light emitters and a detector. The detector is configured to detect light emitted by the emitters that interacts with a patient tube connected to the priming sensor. A processor of a medical fluid delivery device causes the emitters to operate in a sweep pattern during a sweep period. The processor receives output data from the detector that is indicative of light detected during the sweep period. The processor creates an output waveform corresponding to the sweep period based on the output data and compares the output waveform to at least one reference waveform to determine one of (a) a no-tube state, (b) a dry tube state, or (c) a wet tube state. The processor provides an output indicative of the comparison for operation of the medical fluid delivery device. | 2020-10-08 |
20200316281 | OPEN SURFACE GRAPHITIC MATERIALS FOR ADSORPTION OF CYTOKINES FROM BLOOD - The present disclosure is directed to methods of removing proteins, including cytokines, from blood and blood products, the methods comprising contacting the blood or blood product with a form of carbon having high graphitic contents and slit-shaped mesopores and macropores, the pore size dimensions chosen to be comparable to the size of the proteins, wherein the contacting results in the removal of high levels of the protein from the blood or blood product in minutes or hours. | 2020-10-08 |
20200316282 | BIOLOGICAL COMPONENT COLLECTION DEVICE WITH INTERNAL PRESSURE SENSOR AND METHOD - In a blood transfusion system (a blood transfusion kit, a blood transfusion kit for emergency blood transfusion, or a method of using a blood transfusion kit), a flow path through which blood flows is formed using a tube having a channel therein. The flow path includes: a first path that connects an upstream path and a downstream path and has a leukocyte removal filter removing leukocytes at an intermediate position of the channel and a second path that connects the upstream path and the downstream path and bypasses the leukocyte removal filter. | 2020-10-08 |
20200316283 | Automated Extracorporeal Blood Treatment Apparatus - The present invention provides an extracorporeal dialysis apparatus which allows the automation of some operations in order to make possible a safe home treatment or to facilitate the treatment process for example the priming and/or the blood return process. Thus, the object is to automatically perform a series of processes from hemodialysis preparation to treatment completion safely, reliably and speedily, and to significantly reduce the labor and supply costs. | 2020-10-08 |
20200316284 | METHOD OF REMOVING BLOOD FROM AN EXTRACORPOREAL BLOOD CIRCUIT, TREATMENT APPARATUS, AND TUBE SYSTEM - The present invention relates to a method of removing blood from an extracorporeal blood circuit following termination of a blood treatment session, wherein blood is concurrently removed both from an arterial conduit portion and from a venous conduit portion of the extracorporeal blood circuit. It further relates to a method for recognizing and/or eliminating air inclusions in or from an extracorporeal blood circuit and a treatment apparatus as well as a tube system. | 2020-10-08 |
20200316285 | DEVICES, METHODS, AND SYSTEMS FOR PRIMING, SEPARATING, AND COLLECTING BLOOD COMPONENTS - A photopheresis system ( | 2020-10-08 |
20200316286 | MEDICAL DEVICE FOR CONSTIPATION PREVENTION, COPROSTASIS REMOVAL AND GOOD BOWEL MOVEMENT - A medical device includes: a hollow body part formed in a predetermined between shape; a head part provided at a tip portion thereof with a discharge port for discharging cleaning water and detachably coupled to a front end of the body part; a connection part connected to a shower hose and a rear end of the body part and provided with a control valve for controlling water supply, a water flow rate and a water pressure; a water purification tube built in the body part and provided with leakage preventing grilles at both ends thereof; and a purified water discharge part provided inside the head part and configured to remove foreign substances in the water by using a filter. | 2020-10-08 |
20200316287 | Trans Anal Irrigation Platform with Bed Module - A trans anal irrigation device that can be used on a bed. The device includes a rectal catheter connected to an irrigation fluid supply. A waste collection bag is also connected to the catheter. The catheter may be insertable in a seat attached to a fluid supply line. A valve in one of the catheter or seat selectably allows or prevents fluid communication between the catheter and a waste collection bag. The catheter may include an inflationless cuff made of a flexible material that permits it to be inserted in the rectum to prevent leakage around the exterior of the catheter. | 2020-10-08 |